An investigation on behalf of investors in shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) was announced over potential breaches of fiduciary duties by certain officers and directors at Portola Pharmaceuticals.

The investigation by a law firm concerns whether certain Portola Pharmaceuticals officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Francisco, CA based Portola Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options.

On March 24, 2016, Portola Pharmaceuticals Inc announced data from the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study, which evaluated the superiority of extended-duration anticoagulation with oral betrixaban compared with standard of care anticoagulation with injectable enoxaparin for the prevention of venous thromboembolism (VTE), or blood clots, in acute medically ill patients.

On September 5, 2017, Portola Pharmaceuticals Inc announced that the Company's oral anticoagulant Bevyxxa (betrixaban) would launch in November 2017 at the earliest, and possibly as late as the first quarter of 2018.
Having previously projected a September 2017 launch for Bevyxxa, Portola Pharmaceuticals Inc advised investors that the U.S. Food and Drug Administration would require additional time to complete review of a post-approval change to the product.